Prognosis is a horizon scanning service that monitors emerging health technologies as they go through clinical trial development and the regulatory approval process.
I am looking for…
View a sampling of our Prognosis reports.
Loxicodegol (NKTR-181) is a first-in-class full mu-opioid receptor agonist proposed for the treatment of chronic low back pain in adults. This new molecular entity is believed to allow analgesia and inhibit euphoria by penetrating the blood-brain barrier more slowly that currently available opioids, thereby reducing the release of dopamine and inhibiting the effects of euphoria and lowering the potential for abuse.
Nuzyra (omadacycline) is an oral and intravenous aminomethylcycline antibiotic for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection. It is designed to surmount certain forms of antibiotic resistance found in community-acquired infections.
Iclaprim is an intravenous antibacterial agent for the treatment of acute bacterial skin and skin structure infection suspected or known to be due to Gram positive bacteria, including infections due to multidrug-resistant bacteria. Iclaprim is a novel diaminopyrimidine and an inhibitor of dihydrofolate reductase (DHFR) that has shown potent in vitro activity against Gram-positive bacteria, including methicillin resistant Staphylococcus aureus (MRSA, vancomycin-intermediate and vancomycin-resistant S. aureus and macrolide-, quinolone- and trimethoprim-resistant strains. Iclaprim has also demonstrated activity against Streptococcus pneumoniae, including penicillin-, erythromycin-, levofloxacin- and trimethoprim/sulfamethoxazole-resistant strains.
Zolgensma (onasemnogene abeparvovec; formerly AVXS-101) is an adeno-associated virus 9 vector containing the SMN1 gene that is proposed for the treatment of spinal muscular atrophy (SMA) type 1. Zolgensma is intended to replace the defective SMN1 gene with a functional copy that can create SMN protein, thus preventing the loss of motor neurons and further muscle degeneration in patients with SMA type 1.
Dextenza is a sustained-release dexamethasone hydrogel intracanalicular insert for the treatment of ocular pain after ophthalmic surgery. The insert is a rod-shaped biodegradable hydrogel intracanalicular device that delivers 0.4 mg dexamethasone in sustained and tapered release over 4 weeks. The hydrogel is conjugated with fluorescein to enable visualization through eye tissue for retention monitoring. Dextenza is inserted through the inferior punctum into the canaliculus of the operative eye following surgery. It does not require removal after therapy. The device dissolves after remaining in the eye for approximately 30 days and is cleared through the nasolacrimal duct.